Verapamil (versus unexposed)

Table   Graphic  
individual studies
OutcomeTE95% CIn casesn exposedkPub. bias Congenital malformations All congenital malformations (majors, minors, majors and minors, or unspecified) Weber-Schoendorfer, 2008 12.51[1.01; 6.28]3956not evaluable Limb defects Weber-Schoendorfer, 2008 11.89[0.10; 36.98]355not evaluable Major congenital malformations Weber-Schoendorfer, 2008 11.91[0.42; 8.63]1655not evaluable Neural Tube Defects Medveczky, 2004 12.11[0.12; 37.05]1,2028not evaluable Growth parameters and prematurity Preterm (< 37 weeks) Weber-Schoendorfer, 2008 Vaclavik - Verapamil, 2024 22.69[1.34; 5.44]5970not evaluable Low birth weight (< 2500g) Vaclavik - Verapamil, 2024 12.61[1.58; 4.31]-18not evaluable Maternal consequences Caesarean Vaclavik - Verapamil, 2024 11.76[1.21; 2.55]-43not evaluable Neonatal disorders Low Apgar score (< 7) (NOS) Vaclavik - Verapamil, 2024 11.58[0.97; 2.58]-19not evaluable Intrauterine deaths Early intrauterine death (< 22 weeks) Weber-Schoendorfer, 2008 10.90[0.32; 2.57]6358not evaluable Elective/induced termination of pregnancy Weber-Schoendorfer, 2008 11.78[0.61; 5.24]3462not evaluable Late intrauterine deaths (> 22 weeks) Weber-Schoendorfer, 2008 12.25[0.27; 19.02]758not evaluable0.050.01.0

- About - Master protocol - Browse exposition - RSS - Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons